Organic Process Research & Development 2006, 10, 723−726
Identification of Ammonium Chloride as an Effective Promoter of the
Asymmetric Hydrogenation of a â-Enamine Amide
Andrew M. Clausen,* Brianne Dziadul, Kristine L. Cappuccio, Mahmoud Kaba, Cindy Starbuck, Yi Hsiao,† and
Thomas M. Dowling
Merck & Co., Inc., Process Research & DeVelopment (Process Research), P.O. Box 2000,
Rahway, New Jersey 07065, U.S.A.
Abstract:
This examination led us to conclude that the batches of
substrate performing at the upper end of the range contained
a species present in low concentration which promoted both
conversion and desired enantioselectivity. This species was
ultimately identified as ammonium chloride. The presence
of a substoichiometric amount of ammonium chloride relative
to the substrate had a tonic effect on the performance of the
hydrogenation. Similar dependence on halide salt additives
with the same and similar catalyst systems have been
observed before, yet in those cases, the halide salt species
were effective only when added in much higher concentra-
tions.4-6
An investigation into the cause of substrate specific hydrogena-
tion performance variability was conducted. A significant and
unexpected correlation was observed between apparent pH of
a solution of the substrate and rate of conversion and enanti-
oselectivity. This observation led to the examination of low and
variable levels of native ammonium chloride in different lots
of substrate. The presence of ammonium chloride was found
to have a positive effect on reaction rate and enantioselectivity
when controlled within a relatively narrow range. Optimal
performance was achieved with a mole ratio of 1:1 ammonium
chloride to catalyst.
Experimental Section
Hydrogenation of Enamine Amide. Methanol (230 mL)
is charged to a reactor with 25 g of enamine amide. The
resulting slurry is degassed followed by the addition of 0.003
mol equiv (0.046 g) of [(COD)RhCl]2 dimer and 0.0031 mol
equiv (0.104 g) of Josiphos SL-J002-1 ligand (Solvias). The
reaction mixture is heated to 50 °C and hydrogenated at 100
psig (or 115 psi). After 16 h at temperature and under
hydrogen pressure, the batch is cooled to 20 °C and sampled
to analyze for percent conversion and enantiomeric excess.
HPLC Method for Conversion. Percent conversion of
enamine amide to the freebase of sitagliptin phosphate was
analyzed by reverse phase HPLC on an Agilent 1100
according to the following conditions: column, Agilent
Extend C-18, 150 mm × 4.6 mm i.d., 5 µm particles; eluent
A, 1.21 g of TRIS (Sigma), 800 mL of water, 200 mL of
methanol (EM Science), 90 µL of concentrated hydrochloric
acid (Fisher); eluent B, 1.21 g of TRIS (Sigma), 200 mL of
water, 800 mL of methanol (EM Science), 90 µL of
concentrated hydrochloric acid (Fisher); gradient, eluent B,
45% at 0 min to 76% at 8 min held at 76% to 15 min,
reequilibrated at initial conditions for 5 min prior to next
injection.; flow rate 2.0 mL/min; UV detection at 215 nm;
injection volume 5 µL; temperature, 23 °C. Typical retention
times were: sitagliptin, 4.2 min; enamine amide, 5.9 min;
dimer-like impurity, 12.3 min. Sample preparation: pipet 1
mL of hydrogenation stream into a 50-mL volumetric flask
and dilute with eluent A.
Introduction
Sitagliptin phosphate is a dipeptidyl peptidase IV (DPP-
IV) inhibitor which is being studied by Merck & Co., Inc.
for the treatment of diabetes.1 Commercial manufacture of
the drug substance involves two isolated steps (see Scheme
1).2,3 Obtaining the desired compound in high yield relies
heavily on the novel enantioselective hydrogenation of an
unprotected â-enamine amide. Such syntheses, while power-
ful, have not been completely characterized, making predic-
tion of the effect of hydrogenation conditions and additives
difficult.
During the development of this process, it was found that
while individual lots of the starting material enamine amide
gave consistent hydrogenation performance (i.e., rate and
enantioselectivity) there was significant variability across lots.
Results for the hydrogenation ranged from 82% conversion
and 89% enantiomeric excess to 99% conversion and 95%
enantiomeric excess. Process capabilities could tolerate these
fluctuations, but such fluctuations would translate into yield
swings of up to at least 21%. Therefore, an exhaustive
investigation into the source of this variable performance
was initiated.
* To whom correspondence should be addressed. E-mail: andrew_clausen@
merck.com.
† Process Research.
(1) Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.;
Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.;
McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R.
S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.;
Weber, A. E. J. Med. Chem. 2005, 48, 141-151.
(2) Hsiao, Y.; Rivera, N. R.; Rosner, T.; Krska, S. W.; Njolito, E.; Wang, F.;
Sun, Y.; Armstrong, J. D.; Grabowski, E. J. J.; Tillyer, R. D.; Spindler, F.;
Malan, C. J. Am. Chem. Soc. 2004, 126, 9918-9919.
HPLC Method for Enantiomeric Excess. A normal
phase chiral HPLC method was used to determine enantio-
(4) Fagnou, K.; Lautens, M. Angew. Chem., Int. Ed. 2002, 41, 26-47.
(5) Lautens, M.; Fagnou, K. J. Am. Chem. Soc. 2001, 123, 7170-7171.
(6) Leong, P.; Lautens, M. J. Org. Chem. 2004, 69, 2194-2196.
(3) Cypes, S. H.; Wenslow, R. M., Jr.; Thomas, S. M.; Chen, A. M.; Dorwart,
J. G.; Corte, J. R.; Kaba, M. Org. Process Res. DeV. 2004, 8, 576-582.
10.1021/op050232o CCC: $33.50 © 2006 American Chemical Society
Published on Web 05/17/2006
Vol. 10, No. 4, 2006 / Organic Process Research & Development
•
723